Literature DB >> 28124507

Fatty liver promotes fibrosis in monkeys consuming high fructose.

Michael A Cydylo1, Ashley T Davis1, Kylie Kavanagh1.   

Abstract

OBJECTIVE: Nonalcoholic fatty liver diseases (NAFLD) are related to development of liver fibrosis which currently has few therapeutic options. Rodent models of NAFLD inadequately model the fibrotic aspects of the disease and fail to demonstrate the spectrum of cardiometabolic diseases without genetic manipulation. This study aimed to document a monkey model of fatty liver and fibrosis, which naturally develop cardiometabolic disease pathophysiologies.
METHODS: Twenty-seven cynomolgus monkeys (Macaca fascicularis) fed diets either low or high in simple carbohydrates, supplied as fructose [control and high-fructose diet (HRr)], on low-fat, cholesterol-free background were studied. The HFr was consumed for up to 7 years, and liver tissue was histologically evaluated for fat and fibrosis extent.
RESULTS: The HFr diet increased steatosis, and its extent was related to duration of fructose exposure. Lipid droplet size also increased with HFr duration; however, compared with control, the lipid droplets were smaller on average. Fibrosis extent was significantly greater with fructose feeding and was predicted by fructose exposure, extent of fatty liver, and age.
CONCLUSIONS: These data are the first to demonstrate that high-carbohydrate diets alone can generate both liver fat and fibrosis and thus allow further study of mechanisms and therapeutic options in the translational animal model.
© 2017 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28124507      PMCID: PMC5301457          DOI: 10.1002/oby.21720

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


Introduction

Non-alcoholic fatty liver diseases (NAFLD) are prevalent in developed and developing countries (1) and increase risk for cardiometabolic diseases (2). Fatty liver has been attributed to calories excess, and specifically to calories supplied as fructose (3). Controversy exists regarding the role fructose plays, as it is typically consumed within diets characterized by excess calories, high dietary fat and cholesterol. These combined dietary factors drive fatty liver and liver fibrosis in human populations, however they do not consistently produce representative disease in rodents or produce NAFLD through pathways that are implicated in human disease (4). Rodent studies indicate fructose and high carbohydrate diets potently drive fatty liver, however rodents have far greater lipogenesis rates and thus dietary effects in this model may be exaggerated (5). Rodents also have dissimilar primary sites of lipogenesis, inflammatory responses, toll like receptor expression patterns and do not readily develop hepatic fibrosis, which is the disease feature that is the most difficult to induce experimentally and is without therapeutic options in people (4, 6–8). We have previously shown that high carbohydrate consumption as fructose rapidly causes hepatitis and over time drives fatty liver development in monkeys (9). The current study was undertaken to extend these findings by examining hepatic fibrosis and steatosis in fructose-fed monkeys.

Methods

All procedures were approved and followed the guidelines of the Institutional Animal Care and Use Committee of Wake Forest University Health Sciences. Primates, Macaca fasciculus (n=27), were fed one of two diets: a control diet (CTL; Diet 5038, LabDiet, Purina, St. Louis, MO, n=10) or a high fructose diet (HFr; n=17) which have been previously described in detail (9). The CTL diet was high in carbohydrates (69% of calories), with less than 3% glucose and 0.5% fructose supplying the calories. The HFr diet was equivalent in the percentage of calories supplied by carbohydrates however 24% of the total caloric intake was supplied from fructose. The HFr cohort was fed the diet for up to seven years (mean 2.75 years, range 0.27 – 6.6 years; Figure 1A), which approximates 1 to 20 human years, and were older and heavier than CTL monkeys, as previously described (9). Control monkeys had lifelong exposure to their diet condition.
Figure 1

Liver tissue was evaluated from 17 monkeys consuming fructose for 0.27 – 6.6 years, with the number assessed depicted in A. Fructose consumption increased the number of lipid droplets (B) however reduced average lipid droplet size (C) in the liver as compared to monkeys eating a fructose-free control diet. Fibrosis was increased in fructose fed monkeys when measured from the entire histological section (D) and from triplicate parenchymal regions of interest (E). Representative histological examples of liver stained for collagen are shown from a control monkey (F, a severely steatotic monkey fed fructose (G), and a monkey with high fibrosis and moderate steatosis (H).

* indicates significance, with the adjusted p-values (age and bodyweight used as covariates) displayed

Liver tissue collected at necropsy from monkeys was fixed and stained using H&E and Masson’s trichrome (MTC). Sections were assessed for steatosis by lipid droplet number and size and for fibrosis (additional detail available in Supplementary Information). Data were analyzed by analysis of covariance using age and bodyweight as covariates, associations were assessed Pearson’s correlation coefficients, and multiple regression modeling was employed using Statistica (StatSoft Inc., Tulsa, OK). A p<0.05 was used to denote significance. Data are reported as mean ± standard error.

Results

Fructose-fed monkeys were heavier than CTL animals (3.03±0.09kg vs. 5.42±0.83kg; p=0.04). Fructose diets increased the number of lipid droplets, or steatosis score (p<0.001; Figure 1B, graph modified from (9)) but the droplets were of smaller average diameter (p=0.002) (Figure 1C). Fructose consumption significantly increased liver collagen content. Figures 1D and E show that the area stained for collagen in hepatic tissue was increased with fructose consumption when measured as either a percentage of the entire histological section (p=0.03) or the liver parenchyma that was distributed between the portal triads (p=0.007). Representative sections (Figure 1 F–H) illustrate pathological features resembling those seen in human NAFLD. Association analyses from data obtained from the fructose-consuming animals only (n=17; Figure 2) show that the number and diameter of the lipid droplets increased with longer consumption of fructose-containing diet. The steatosis score, or number of droplets, also had a significant positive relationship with hepatic fibrosis. CD3 cell counts were non-significantly higher in HFr monkeys (p=0.36) and not related to liver fat or fibrosis.
Figure 2

Associations between fibrosis and steatosis (A), steatosis (B) lipid droplet size (C), and fibrosis (D) and duration of high fructose consumption in monkeys. Pearson’s correlation coefficients and p-values are shown on each graph.

To examine the relative contributions of steatosis score, age, weight, duration of consumption, sex, and the experimental diets fed on liver fibrosis, a multiple regression analysis was conducted, with percent area of the liver staining positive for collagen as the outcome variable. The overall model was highly significant (Table 1; p<0.001) only with diet type (HFr vs. CTL), the extent of steatosis and age and being retained as significant predictors. Fructose exposure had the greatest magnitude of effect as compared to steatosis score, with age having a nominal effect on fibrosis.
Table 1

Multivariate regression modeling results for liver fibrosis show that fructose exposure, the extent of liver fat and age all significantly influence collagen deposition.

Model VariableR2ß-coefficientp-value
Fructose Diet0.330.640.004
Steatosis Score0.230.520.02
Age0.440.0880.0006

Discussion

This report is the first to demonstrate, using a non-human primate animal model, that a high carbohydrate diet not augmented with dietary fat or cholesterol drives the important features of NAFLD including fibrosis (4, 9, 10). The demonstration of these pathologies in a non-human primate is relevant to the human disease as they have both comparable gastrointestinal and hepatic anatomies and functions, and immunological responses (11). While there has been controversy on the exact cause of steatosis, whether excess calories, fat, fructose, or a combination of the three, this study produced clear evidence that just carbohydrate consumption as fructose induces fatty liver and also promotes fibrotic processes. These results further confirm that non-human primates, unlike rodents, develop fibrosis as part of their NAFLD expression in response to a carbohydrate diet challenge. Only one other primate model, Macaca radiata, describes fibrosis accompanying steatosis (12). In this monkey model, older age was also identified as a risk factor for disease however fibrosis extent was described categorically and the interactions of age and fat were not explored. In our larger cohort of monkeys, the fibrosis extent measured was variable among individuals, as reflected by lack of a direct significant relationship between the duration of diet consumption and liver fibrosis, while steatosis development with the fructose diet was more consistent. This represents an opportunity to further investigate the mechanisms of fibrotic processes and why certain individuals are more vulnerable to this negative consequence of consuming a high simple carbohydrate or fructose-containing diet. Confidence in our histological results is high as the steatosis and fibrosis outcomes were measured by two different methods and produced consistent results: increased fat and fibrosis in the fructose-fed monkeys. However, these results do not implicate fructose specifically in fibrosis induction, as this study did not include a group of monkeys consuming comparable amounts of glucose, and it is possible that dextrose may also produce similar results. In rodent and human studies, fructose is more potent in inducing fatty liver (13, 14) which should drive fibrosis in a vulnerable clinical population. This hypothesis is supported by clinical reports of fructose being related to liver fibrosis in patients with nonalcoholic hepatosteatitis, even when controlling for caloric intake in statistical models (15). Our monkey cohort was predominantly female, and studies have shown that NAFLD prevalence is higher in males than females (16). Thus, our findings may underestimate the effects of a high carbohydrate diet on fat and fibrosis in the liver of a larger population. The predominant strength for this study was the use of cynologus monkeys as the animal model, and the long duration of dietary manipulation which to date has not yet been reported. Ectopic fat deposition in the liver is linked to the development of metabolic diseases (17). In this regard, monkeys are uniquely translational as rodents do not spontaneously develop diabetes or cardiovascular disease in the absence of genetic manipulation, while monkeys will develop both without experimental intervention (18, 19). Human clinical trials would be ideal, however long-term controlled dietary studies are difficult and liver samples cannot be routinely collected. We conclude that the monkey is the optimal model to study NAFLD etiologies and progression, and to evaluate potential therapeutic options for reversal of fat and fibrosis deposition with amelioration of related cardiometabolic diseases.
  19 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 2.  Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models.

Authors:  Werner G Bergen; Harry J Mersmann
Journal:  J Nutr       Date:  2005-11       Impact factor: 4.798

3.  Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis.

Authors:  Heather Basciano; Abigale E Miller; Mark Naples; Christopher Baker; Rita Kohen; Elaine Xu; Qiaozhu Su; Emma M Allister; Michael B Wheeler; Khosrow Adeli
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-09       Impact factor: 4.310

4.  Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes.

Authors:  Andrew A Bremer; Kimber L Stanhope; James L Graham; Bethany P Cummings; Wenli Wang; Benjamin R Saville; Peter J Havel
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

5.  Is fructose a story of mice but not men?

Authors:  John L Sievenpiper; Russell J de Souza; Cyril W C Kendall; David J A Jenkins
Journal:  J Am Diet Assoc       Date:  2011-02

Review 6.  Immune senescence in aged nonhuman primates.

Authors:  Kristen Haberthur; Flora Engelman; Alex Barron; Ilhem Messaoudi
Journal:  Exp Gerontol       Date:  2010-06-15       Impact factor: 4.032

Review 7.  Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis.

Authors:  John L Sievenpiper; Russell J de Souza; Arash Mirrahimi; Matthew E Yu; Amanda J Carleton; Joseph Beyene; Laura Chiavaroli; Marco Di Buono; Alexandra L Jenkins; Lawrence A Leiter; Thomas M S Wolever; Cyril W C Kendall; David J A Jenkins
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

8.  Macaca radiata (bonnet monkey): a spontaneous model of nonalcoholic fatty liver disease.

Authors:  Perumal Nagarajan; Ramasamy Venkatesan; Mahesh Kumar; Abul Usmani; Subeer S Majumdar
Journal:  Liver Int       Date:  2008-07       Impact factor: 5.828

9.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.

Authors:  Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

10.  Genomic responses in mouse models poorly mimic human inflammatory diseases.

Authors:  Junhee Seok; H Shaw Warren; Alex G Cuenca; Michael N Mindrinos; Henry V Baker; Weihong Xu; Daniel R Richards; Grace P McDonald-Smith; Hong Gao; Laura Hennessy; Celeste C Finnerty; Cecilia M López; Shari Honari; Ernest E Moore; Joseph P Minei; Joseph Cuschieri; Paul E Bankey; Jeffrey L Johnson; Jason Sperry; Avery B Nathens; Timothy R Billiar; Michael A West; Marc G Jeschke; Matthew B Klein; Richard L Gamelli; Nicole S Gibran; Bernard H Brownstein; Carol Miller-Graziano; Steve E Calvano; Philip H Mason; J Perren Cobb; Laurence G Rahme; Stephen F Lowry; Ronald V Maier; Lyle L Moldawer; David N Herndon; Ronald W Davis; Wenzhong Xiao; Ronald G Tompkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

View more
  21 in total

Review 1.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

2.  Magnesium isoglycyrrhizinate ameliorates high fructose-induced liver fibrosis in rat by increasing miR-375-3p to suppress JAK2/STAT3 pathway and TGF-β1/Smad signaling.

Authors:  Yan-Zi Yang; Xiao-Juan Zhao; Hong-Jiang Xu; Shan-Chun Wang; Ying Pan; Shui-Juan Wang; Qiang Xu; Rui-Qing Jiao; Hong-Mei Gu; Ling-Dong Kong
Journal:  Acta Pharmacol Sin       Date:  2018-12-19       Impact factor: 6.150

Review 3.  The Science of Obesity Management: An Endocrine Society Scientific Statement.

Authors:  George A Bray; William E Heisel; Ashkan Afshin; Michael D Jensen; William H Dietz; Michael Long; Robert F Kushner; Stephen R Daniels; Thomas A Wadden; Adam G Tsai; Frank B Hu; John M Jakicic; Donna H Ryan; Bruce M Wolfe; Thomas H Inge
Journal:  Endocr Rev       Date:  2018-04-01       Impact factor: 19.871

4.  Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates.

Authors:  Leigh Goedeke; Liang Peng; Valle Montalvo-Romeral; Gina M Butrico; Sylvie Dufour; Xian-Man Zhang; Rachel J Perry; Gary W Cline; Paul Kievit; Keefe Chng; Kitt Falk Petersen; Gerald I Shulman
Journal:  Sci Transl Med       Date:  2019-10-02       Impact factor: 17.956

5.  Glomerular Hyperfiltration Is Associated with Liver Disease Severity in Children with Nonalcoholic Fatty Liver Disease.

Authors:  Toshifumi Yodoshi; Ana Catalina Arce-Clachar; Qin Sun; Lin Fei; Kristin Bramlage; Stavra A Xanthakos; Francisco Flores; Marialena Mouzaki
Journal:  J Pediatr       Date:  2020-05-04       Impact factor: 4.406

6.  Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-β1/Smads signalling.

Authors:  Lin Song; Tian-Yu Chen; Xiao-Juan Zhao; Qiang Xu; Rui-Qing Jiao; Jian-Mei Li; Ling-Dong Kong
Journal:  Br J Pharmacol       Date:  2019-04-24       Impact factor: 8.739

Review 7.  Molecular aspects of fructose metabolism and metabolic disease.

Authors:  Mark A Herman; Morris J Birnbaum
Journal:  Cell Metab       Date:  2021-10-06       Impact factor: 27.287

Review 8.  Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.

Authors:  Peter J Havel; Paul Kievit; Anthony G Comuzzie; Andrew A Bremer
Journal:  ILAR J       Date:  2017-12-01

Review 9.  Nonhuman Primates and Translational Research-Cardiovascular Disease.

Authors:  Laura A Cox; Michael Olivier; Kimberly Spradling-Reeves; Genesio M Karere; Anthony G Comuzzie; John L VandeBerg
Journal:  ILAR J       Date:  2017-12-01

10.  High fructose-containing drinking water-induced steatohepatitis in rats is prevented by the nicotinamide-mediated modulation of redox homeostasis and NADPH-producing enzymes.

Authors:  S S Loza-Medrano; L A Baiza-Gutman; L Manuel-Apolinar; R García-Macedo; L Damasio-Santana; O A Martínez-Mar; M C Sánchez-Becerra; M Cruz-López; M A Ibáñez-Hernández; M Díaz-Flores
Journal:  Mol Biol Rep       Date:  2019-10-24       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.